ExodusPoint Capital Management’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.28M Buy
347,388
+154,048
+80% +$1.23M 0.02% 705
2026
Q2
$1.69M Buy
193,340
+109,031
+129% +$825K 0.01% 886
2026
Q1
$647K Sell
84,309
-283,572
-77% -$1.94M 0.01% 1120
2025
Q4
$728K Buy
367,881
+205,498
+127% +$466K 0.01% 1090
2025
Q3
$399K Buy
+162,383
New +$418K ﹤0.01% 1237
2024
Q4
– Sell
-135,029
Closed -$502K – 1748
2024
Q3
$502K Buy
+135,029
New +$625K ﹤0.01% 1183
2024
Q1
– Sell
-23,558
Closed -$118K – 1695
2023
Q4
$118K Buy
+23,558
New +$73.9K ﹤0.01% 1341
2023
Q2
– Sell
-10,262
Closed -$19K – 2030
2023
Q1
$19K Buy
+10,262
New +$31.9K ﹤0.01% 1691
2021
Q2
– Sell
-35,312
Closed -$838K – 2556
2021
Q1
$838K Buy
+35,312
New +$915K 0.01% 1019
2020
Q4
– Sell
-11,892
Closed -$82K – 2137
2020
Q3
$82K Sell
11,892
-85,579
-88% -$853K ﹤0.01% 1612
2020
Q2
$1.2M Buy
97,471
+15,850
+19% +$89.5K 0.03% 652
2020
Q1
$235K Sell
81,621
-10,532
-11% -$52.7K 0.01% 722
2019
Q4
$349K Buy
+92,153
New +$157K 0.01% 1058

Other funds holding IBRX

ExodusPoint Capital Management's IBRX Position: Q3 2026 in Review

ExodusPoint Capital Management increased its ImmunityBio (IBRX) stake by 80% in Q3 2026, buying an estimated $1.23M and bringing the position to 347,388 shares worth $3.28M. The position accounts for 0.02% of the portfolio, ranked #705.

ExodusPoint Capital Management first reported a position in IBRX in Q4 2019 and has held it in 13 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • ExodusPoint Capital Management held 347,388 shares of ImmunityBio worth $3.28M as of Q3 2026.
  • ExodusPoint Capital Management bought 154,048 ImmunityBio shares in Q3 2026, an estimated $1.23M.
  • ImmunityBio made up 0.02% of ExodusPoint Capital Management's portfolio in Q3 2026, its #705 holding.
  • ExodusPoint Capital Management first reported a position in ImmunityBio in Q4 2019 and has held it in 13 quarters since.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.